Prescription for Better Access

In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies. 

Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
Eric Faulkner, President, Passage Health Associates
ADVI Health
Alliance for Regenerative Medicine
ARPA-H
Bespoke Gene Therapy Consortium
Blue Bird Bio
Blue Cross Blue Shield
Medicare DRG Rates
NICE (National Institute for Health and Care Excellence)
Novartis
Passage Health Associates
REMS Program
Single Case Agreements
Spark Therapeutics

Medical terminology referenced in this episode:

• Alzheimer's
• Aspheresis
• CAR T therapy
• Hemophilia
• Hepatitus C
• Luxturna
• Metachromatic leukodystrophy 
• Myeloablative Conditioning
• Sickle Cell Disease
• SMA treatment
• Spinraza
• Vaso Occlusive Crises
• Zolgensma